Carbonic anhydrase inhibitors act on the kidney by inhibiting the carbonic anhydrase enzyme in the proximal convoluted tubules, preventing the reabsorption of bicarbonate ions. This leads to increased bicarbonate excretion, sodium excretion, water loss, and metabolic acidosis. They are used to treat glaucoma by decreasing aqueous humor production and lowering intraocular pressure, as well as acute mountain sickness by decreasing cerebral spinal fluid production and lowering intracranial pressure. Common side effects include acidosis, hypokalemia, and drowsiness.